Genetic vaccination against leishmaniasis

Vaccine

Volumn 12, Issue 16, 1994, Pages 1534-1536

  Xu, Damo ^a   Liew, F Y ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

genetic vaccine; Leishmaniasis; surface glycoprotein gp63

Indexed keywords

CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; LEISHMANIA VACCINE; PARASITE ANTIGEN;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; IMMUNE RESPONSE; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION;

ANIMAL; GENETIC VECTORS; INTERFERON TYPE II; LEISHMANIASIS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES;

EID: 0027997083     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(94)90079-5     Document Type: Article

References (10)

1. The Leishmaniasis
2. The present and future of vaccination for cutaneous leishmaniasis.
3. Immunology of leishmaniasis
4. Oral Salmonella typhimurium (AroA) vaccine expressing a major leishmanial surface protein (gp63) preferentially induced Th1 cells and protective immunity against leishmaniasis
5. Recombinant gp46/M-2 vaccinia viruses protect against Leishmania infection
6. Effective immunisation against cutaneous leishmaniasis with recombinant BCG expressing the Leishmania surface proteinase, gp63
7. Identification of the promastigote surface protease in seven species of Leishmania
8. Molecular cloning of the major surface antigen of Leishmania
9. Effective immunisation against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes
10. The adjuvant effect of IL-12 in a vaccine against Leishmania major